Introduction
Nimodipine is a calcium antagonist of the 1,4-dihydropyridine class ( Fig.1 ). At present, nimodipine is clinically used in over 50 foreign countries for the treatment of acute and chronic cerebrovascular diseases. In Japan, the drug has been investigated in a series of clinical trials in healthy subjects and patients with vascular dementia. We performed the population pharmacokinetic (PPK) analysis with plasma concentration data from these Japanese clinical trials to investigate the factors which may affect nimodipine pharmacokinetics as well as its intra-and inter-individual variabilities. 
1) Data set for analysis
The plasma concentration data from formal pharmacokinetic (PK) studies in healthy subjects, as well as PK screening in phase III long term studies were collected for the PPK analysis. In the formal PK studies, more than 10 blood samplings were conducted per subject, according to the prescribed sampling times in the study protocol. On the other hand, only 2 to 3 blood samplings per patient were conducted after reaching steady state in the PK screening. These samplings were conducted at the same time with the blood sampling for clinical laboratory tests. Although blood sampling time was not defined in the protocol for PK screening, it was expected to vary patient by patient ("natural random sampling"). Plasma nimodipine concentrations were determined by GC-ECD methods in two different laboratories. The methods were validated in each laboratory and finally "cross-validated" in both laboratories.
2) PPK analysis By using NONMEM2) version V level 1.0, PREDPP version IV level 1.0 and NM-TRN version III level 1.0 which were installed on DEC alpha 4100 with open VMS, a two-compartment model with first-order absorption and proportional error model were applied to the nimodipine concentration-time data. Any variables which may influence parameters in the PK model, such as subject backgrounds (demographic data, clinical lab. test values), administered nimodipine tablet (15mg or 30mg tablet), nimodipine dose per administration (30mg, 60mg or 90 mg) and condition for drug administration (fasting or fed), were evaluated on their data distributions and then with a likelihood comparison test. A p-value of 0.05 was adopted to 
